News | Cardiovascular Surgery | February 16, 2017

First Edwards Intuity Elite Aortic Valve Implanted in Connecticut

Sutureless valve shortens procedure times, meaning less time the patient’s heart is stopped

Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network

February 16, 2017 — Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were the first in Connecticut to implant the Edwards Intuity Elite sutureless aortic valve in two patients at Danbury Hospital. This new technology in aortic valve replacement (AVR) surgery presents a safe and effective option for patients with severe aortic valve disease. The valves were implanted using the Edwards Intuity valve system, a rapid deployment device approved by the U.S. Food and Drug Administration (FDA) in August 2016.

The American Heart Association estimates that more than 5 million Americans are diagnosed with heart valve disease each year. While the disease can occur in any combination of the four heart valves, the aortic and mitral valves are the most commonly affected.

Aortic stenosis mainly affects older people due to a build-up of calcium on the valve’s leaflets. Over a period of time, the aortic valve leaflets stiffen and do not completely open, blocking the normal flow of blood. Some of the symptoms associated with aortic stenosis include dizziness or fainting, shortness of breath, chest pressure or pain. Without treatment, the symptoms worsen over time and may lead to death within a few years. Treatment for valve disease depends on how much disease is in the valve.

The Edwards Intuity Elite valve is built upon the Perimount valve, which has been widely used for more than 20 years. The valve also uses technology from transcatheter heart valves to simplify placement and shorten the duration of the surgery. The Intuity valve differs from standard heart valves by only needing three guiding sutures for placement, instead of 12-15 sutures. 

Passik said, “Because the valves are not sutured in place, fewer steps are necessary, which translates to less time the heart is stopped and the patient is on the heart-lung machine.”  

“The cutting-edge treatment allows us to implant the aortic valve faster, thereby allowing more time to complete other procedures conducted simultaneously with the implantation,” said Gallagher, chief of cardiothoracic surgery. “We are very pleased to offer our patients another less invasive treatment option in AVR surgery.”

For more information: www.edwards.com

Related Content

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
heart valve regurgitation seen on an echocardiogram, cardiac ultrasound, from ASE study
News | Cardiovascular Ultrasound| June 16, 2017
June 15, 2017 – While much attention has been focused on ways to lower heart disease-related injuries and deaths, the
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Sponsored Content | Videos | Heart Valve Technology| June 14, 2017
A discussion with Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Sapien 3 valve for VIV (valve in valve) procedures cleared by FDA
Feature | Heart Valve Technology| June 06, 2017 | Dave Fornell
The U.S. Food and Drug Administration (FDA) has granted market clearance for aortic and mitral valve-in-valve...
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
News | Guidewires| May 30, 2017
A Canadian cardiologist has published a report in the journal Eurointervention describing how he used a Canadian-...
Overlay Init